SCHEMBL968944

SCHEMBL968944

CC(=O)OC(=O)C(Br)(Br)Br

nearest known ligand 0.50

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL968943 0.81
SCHEMBL4855878 0.78 ALDH1A1 (0.45) ALDH1A1TSHRHSD17B10TDP1
SCHEMBL28197846 0.78 ALDH1A1 (0.32) ALDH1A1TSHR
SCHEMBL214755 0.73 ALDH1A1 (0.53) ALDH1A1TSHRHSD17B10TDP1
SCHEMBL4316110 0.73 ALDH1A1 (0.53) ALDH1A1TSHRHSD17B10TDP1
SCHEMBL28112044 0.72 ALDH1A1 (0.36) ALDH1A1TDP1
SCHEMBL19458016 0.71 ALDH1A1 (0.50) ALDH1A1TSHRHSD17B10TDP1
SCHEMBL150680 0.71 ALDH1A1 (0.50) ALDH1A1TSHRHSD17B10TDP1
SCHEMBL21831923 0.71 ALDH1A1 (0.50) ALDH1A1TSHRHSD17B10TDP1
SCHEMBL4644773 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025095793-A1 FORMULATIONS FOR DI- OR TRI-HALOGENATED METHANE GENERATION AND USES THEREOF Ruminant Biotech Corp Limited (NZ) 2025-05-08 WO claimed
CN-117447338-B Lenvatinib intermediate Synthesis method of intermediate 南昌大学第二附属医院 2024-11-15 CN claimed
CN-115710202-B Preparation method and application of apataone key intermediate 江西同和药业股份有限公司 2024-05-03 CN claimed
CN-117447338-A Synthesis method of lenvatinib intermediate 南昌大学第二附属医院 2024-01-26 CN claimed
CN-115710202-A Preparation method and application of apatazone key intermediate 江西同和药业股份有限公司 2023-02-24 CN claimed
EP-3231795-B1 METHOD FOR PREPARING 2,5-DISUBSTITUTED FURAN COMPOUND NINGBO INST MATERIALS TECH & ENG CAS (CN) 2021-09-15 EP claimed
CN-112409305-A Preparation method of 2, 5-diacyl furan compound 中国科学院宁波材料技术与工程研究所 2021-02-26 CN claimed
US-10125110-B2 Method for preparing 2,5-disubstituted furan compound NINGBO INSTITUTE OF MATERIALS TECHNOLOGY & ENGINEERING, CHINESE ACADEMY OF SCIENCES (CN) 2018-11-13 US claimed
US-20170320844-A1 METHOD FOR PREPARING 2,5-DISUBSTITUTED FURAN COMPOUND NINGBO INSTITUTE OF MATERIALS TECHNOLOGY & ENGINEERING, CHINESE ACADEMY OF SCIENCES (CN) 2017-11-09 US claimed
US-4362650-A ORGANOALUMINUM HALIDE, NICKEL COMPOUND INSTITUT FRANCAIS DU PETROLE (FR) 1982-12-07 US claimed
EP-3478295-B1 SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES PHARMACOSMOS HOLDING AS (DK) 2026-05-27 EP disclosed
US-12503591-B2 Liquid crystal polymer, composition, liquid crystal polymer film, laminated material and method of forming liquid crystal polymer film INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2025-12-23 US disclosed
EP-4596051-A2 HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION Pharmacosmos Holding A/s (DK) 2025-08-06 EP disclosed
US-12371563-B2 Liquid crystal polymer, composition, liquid crystal polymer film, laminated material and method of forming liquid crystal polymer film INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) 2025-07-29 US disclosed
CN-120051373-A Laminate and method for producing laminate 日东电工株式会社 2025-05-27 CN disclosed
EP-0373039-B1 New lysoganglioside derivatives FIDIA SPA (IT) 1994-04-06 EP disclosed
US-4801704-A PENICILLINS HOFFMAN-LA ROCHE INC. (US) 1989-01-31 US disclosed
US-4279982-A PRINTOUTS; OXADIAZOLE PHOTOINITIATORS FUJI PHOTO FILM CO., LTD. (JP) 1981-07-21 US disclosed
US-4232106-A Photosensitive compositions containing 2-halomethyl-5-vinyl-1,3,4-oxadiazoles as free radical progenitors FUJI PHOTO FILM CO., LTD. (JP) 1980-11-04 US disclosed
US-4212970-A PHOTOINITIATORS FUJI PHOTO FILM CO., LTD. (JP) 1980-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320844-A1 METHOD FOR PREPARING 2,5-DISUBSTITUTED FURAN COMPOUND ALOX5, PFAS, APEH ALDH1A1 561/4885TSHR 4544/4885HSD17B10 804/4885
US-10125110-B2 Method for preparing 2,5-disubstituted furan compound ALOX5, PFAS, APEH ALDH1A1 561/4885TSHR 4544/4885HSD17B10 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.